What is Obsidian Therapeutics?
Headquartered in Cambridge, Massachusetts, Obsidian Therapeutics is a pioneering biotechnology enterprise dedicated to the development of next-generation cell and gene therapies. The company specializes in creating controllable, engineered therapies that allow for precise regulation of protein activity, a critical factor in enhancing the safety and efficacy of advanced medical treatments. By leveraging its proprietary technology, Obsidian aims to transform the therapeutic landscape for patients suffering from complex and difficult-to-treat conditions.
The firm operates at the intersection of synthetic biology and clinical medicine, maintaining a focus on high-impact therapeutic areas. Its market position is defined by its ability to bridge the gap between foundational scientific discovery and scalable clinical application, supported by a sophisticated intellectual property portfolio and a strategic network of industry partners.
How much funding has Obsidian Therapeutics raised?
Obsidian Therapeutics has raised a total of $209.5M across 2 funding rounds:
Series A
$49.5M
Series C
$160M
Series A (2017): $49.5M with participation from Takeda Ventures, Inc., Atlas Venture, Google Ventures, and Vertex Healthcare VC
Series C (2024): $160M led by Wellington Capital Management, Foresite Capital, and Novo Holdings
Key Investors in Obsidian Therapeutics
Wellington Capital Management
Wellington Capital Management is an independent fiduciary adviser providing comprehensive wealth management and retirement consulting services with a focus on long-term capital preservation.
Foresite Capital
Foresite Capital is a multi-stage investment firm that utilizes data science and deep industry expertise to fund breakthrough innovations at the intersection of technology and biotechnology.
Novo Holdings
Novo Holdings is a Danish private limited liability company and the investment arm of the Novo Nordisk Foundation, focused on long-term value creation in the life sciences sector.
What's next for Obsidian Therapeutics?
With the successful closure of its latest financing round, Obsidian Therapeutics is well-positioned to accelerate its pipeline development and expand its clinical trial footprint. The strategic allocation of this capital will likely prioritize the advancement of lead candidates through regulatory milestones and the scaling of manufacturing capabilities necessary for late-stage clinical evaluation.
Looking ahead, the company is expected to leverage its deep industry partnerships to refine its therapeutic platform, potentially exploring new indications for its engineered cell therapies. As the biotech sector continues to prioritize precision medicine, Obsidian's focus on tunable protein regulation provides a distinct competitive advantage, setting the stage for potential long-term value creation and significant contributions to the future of personalized healthcare.
